PDCD1 and cancer: This contention is supported by findings that administration of ipilimumab or PD-1-targeted MAbs to patients with advanced melanoma is accompanied by rapid diversification of the T cell repertoire (102–104), described by the authors of one of these studies as being “both detrimental and beneficial for patients with cancer” (102).